Ingredient or product comparison
GHK-Cu vs. BPC-157: A Quick Comparison for Context
To further illustrate how WADA's list works, it's helpful to compare GHK-Cu to a peptide that is explicitly banned: BPC-157. This comparison highlights the fine lines and the overarching principles WADA employs. WADA Status Not explicitly named, but prohibited
This source-based comparison does not add ratings or recommend a winner.
- To further illustrate how WADA's list works, it's helpful to compare GHK-Cu to a peptide that is explicitly banned: BPC-157. This comparison highlights the fine lines and the overarching principles WADA employs.
- WADA Status
- Not explicitly named, but prohibited under S0 & S2 categories.
- Explicitly named and prohibited under S2.
- Primary Function
- Wound healing, collagen synthesis, anti-inflammatory, gene modulation.
- Angiogenesis (blood vessel formation), tissue repair, cytoprotective.
- Natural Occurrence
- Naturally occurs in human plasma.
- A synthetic peptide derived from a human gastric protein.
- Main Area of Use
- Cosmetics (topical), in-vitro research.
- In-vitro research (no approved medical use).
- Reason for Scrutiny
- Potent regenerative and healing properties.
- Powerful systemic healing and angiogenic effects.
- This table makes it plain. BPC-157 was so potent and gained so much traction in athletic circles for its injury recovery properties that WADA eventually added it by name to remove all doubt. GHK-Cu operates in the same functional space. The fact that it isn't named yet is irrelevant from a risk perspective. It possesses the exact type of biological activity that WADA targets.